BriaCell Offers New Hope for Breast Cancer Patients

BriaCell Therapeutics (TSE:BCT) has released an update.

BriaCell Therapeutics has announced that the FDA has authorized an Expanded Access Policy allowing metastatic breast cancer patients to receive their novel Bria-IMT™ immunotherapy outside of the current Phase 3 clinical trial. This policy aims to provide additional treatment options for patients who have exhausted other therapies, with the hope of improving care for a disease that remains a leading cause of cancer death among American women.

For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.